Severity
Moderate
FDA Drug recall · Reported June 19, 2024
Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.
Pacira Pharmaceuticals INC recalled Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspensio… - a moderate-severity action.
Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspensio… was recalled by Pacira Pharmaceuticals INC in June 19, 2024. Reason: Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.. Check the official notice for the remedy. Verify recall #D-0546-2024 with the FDA Drug before acting.
The recall
Pacira Pharmaceuticals INC issued this moderate-severity FDA Drug recall-Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C..
Sourced from official FDA Drug enforcement records. Verify recall #D-0546-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0546-2024) was formally reported on June 19, 2024, with the manufacturer initiating the action on May 7, 2024. It is classified under Moderate severity (Class II), with a current status of Ongoing. Pacira Pharmaceuticals INC is listed as the recalling firm, operating out of San Diego, CA. Federal records list the affected scope as 43,768 kits.
The documented reason for this recall is: Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C. Distribution data in the federal record shows the product reached: U.S. Nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
43,768 kits
Related Recalls
6
5 from same agency
Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-001-01. Diluent Vial Label: Diluent, 5mL, Sterile single use, Rx only, Manufactured for Pacira Pharmaceuticals Inc., NDC 65250-002-01. Carton Label: Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-003-01.
Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0546-2024 |
| Date reported | June 19, 2024 |
| Date initiated | May 7, 2024 |
| Recalling firm | Pacira Pharmaceuticals INC |
| Firm location | San Diego, CA |
| Affected scope | 43,768 kits |
| Distribution | U.S. Nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 19, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.